Research on the Mechanism of Action of a Novel Drug for the Treatment of Peripheral Neuropathy
Authors: J. Zhang, L. Wang, Y. Li, H. Chen, S. Liu
Background: Peripheral neuropathy is a common neurological disorder with limited treatment options. This study investigates the therapeutic potential and underlying mechanisms of a novel compound, designated as NSPQ, in a rat model of peripheral neuropathy. Methods: Rats were subjected to chronic constriction injury (CCI) to induce neuropathic pain. NSPQ was administered intraperitoneally for 14 days. Pain behavior was assessed using mechanical allodynia and thermal hyperalgesia tests. Dorsal root ganglia (DRG) and spinal cord tissues were collected for molecular analysis. Protein expression levels of inflammatory cytokines and neurotrophic factors were measured via Western blot and ELISA. Results: NSPQ treatment significantly alleviated mechanical allodynia and thermal hyperalgesia in CCI rats. It reduced the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and increased the levels of anti-inflammatory cytokine IL-10 in DRG and spinal cord. Furthermore, NSPQ upregulated the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Conclusions: NSPQ exerts neuroprotective effects in peripheral neuropathy by modulating inflammatory responses and promoting neurotrophic factor expression, suggesting its potential as a therapeutic agent for neuropathic pain.
